TABLE 4.

Recommended laboratory monitoring of hospitalized patients with COVID‐19

	ASH 63 , 70	ISTH 64	ACC 28	Thrombosis UK/BSH 32 , 65	SSH 61
Laboratory parameter
aPTT	x		x
ALT					x
Creatinine					x
D‐dimer	x	x	x		x
Fibrinogen	x	x	x		x
LDH					x
Platelets	x	x	x		x
PT/INR	x	x	x		x
DIC transfusion management
Nonbleeding patient	Routine blood products not recommended	Maintain: PLT > 25 × 109/L	Maintain: PLT > 20 × 109/L in those with a high bleeding risk or requiring an invasive procedure	Routine blood products not recommended	Not specified
Bleeding patient	Maintain: PLT ≥ 50 × 109/L Fibrinogen ≥ 1.5 g/L INR < 1.8	Maintain: PLT > 50 × 109/L Fibrinogen > 1.5 g/L PT Ratio < 1.5	Maintain: PLT > 50 × 109/L Fibrinogen ≥ 1.5 g/L aPTT or PT ≤ 1.5 × ULN	Maintain: PLT > 50 × 109/L Fibrinogen ≥ 1.5 g/L aPTT or PT ≤ 1.5 × ULN TA 1 g IV for patients without DIC rVIIa and PCC are not recommended given they are prothrombotic	Not specified

ACC, American College of Cardiology; ALT, alanine transaminase; aPTT, activated partial thromboplastin time; ASH, American Society of Hematology; INR, International normal ratio; LDH, lactate dehydrogenase; PCC, prothrombin complex concentrate; PLT, platelet count; PT, protime; rVIIa, recombinant activated factor VIIa; SSH, Swedish Society of Hematology; TA, tranexamic acid; ULN, upper limit of normal.